Are we ready for online tools in decision making for BRCA1/2 mutation carriers?

Journal of Clinical Oncology

Volumn 30, Issue 5, 2012, Pages 471-473

  Evans, D Gareth ^a,b   Howell, Anthony ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ALLELE; BREAST CANCER; BREAST EXAMINATION; CANCER CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; EDITORIAL; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HETEROZYGOTE; HUMAN; MAMMOGRAPHY; MASTECTOMY; MEDICAL DECISION MAKING; NUCLEAR MAGNETIC RESONANCE IMAGING; ONLINE SYSTEM; OVARY CANCER; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY; SINGLE NUCLEOTIDE POLYMORPHISM;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; COMPUTER SIMULATION; DECISION SUPPORT TECHNIQUES; EARLY DETECTION OF CANCER; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; MASS SCREENING; MUTATION; OVARIAN NEOPLASMS; OVARIECTOMY; QUALITY OF LIFE; ULTRASONOGRAPHY, MAMMARY;

EID: 84856823021     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.40.1562     Document Type: Editorial

References (36)

1. Madalinska JB, Hollenstein J, Bleiker E, et al: Quality of life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol 23:6890-6898, 2005
2. Challberg J, Ashcroft L, Lalloo F, et al: Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: Significant bone health issues in those not taking HRT. Br J Cancer 105:22, 2011
3. Hallowell N, Mackay J, Richards M, et al: High-risk premenopausal women's experiences of undergoing prophylactic oophorectomy: A descriptive study. Genet Test 8:148-156, 2004 (Pubitemid 39096757)
4. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, et al: International variation in rates of uptake of preventative option in BRCA1 and BRCA2 mutation carriers. Int J Cancer 122:2017-2022, 2008 (Pubitemid 351441190)
5. Julian-Reynier C, Bouchard L, Evans G, et al: Women's attitudes toward preventive strategies for hereditary breast/ovarian cancer risk differ from one country to another: Differences between Manchester (UK), Marseilles (F) and Montreal (Ca). Cancer 92:959-968, 2001 (Pubitemid 32783086)
6. Evans DGR, Lalloo F, Ashcroft L, et al: Uptake of risk reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependant. Cancer Epidemiol Biomarkers Prev 18(8):2318-2324, 2009
7. Kurian AW, Munoz DF, Rust P, et al: Online tool to guide decisions for BRCA1/2 mutation carriers. J Clin Oncol 30:497-506, 2012
8. Risch HA, McLaughlin JR, Cole DEC, et al: Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68:700-710, 2001 (Pubitemid 32203724)
9. Tryggvadottir L, Sigvaldason H, Olafsdottir GH, et al: Population-based study of changing breast cancer risk in Icelandic BRCA2 mutation carriers, 1920-2000. J Natl Cancer Inst 98:116-122, 2006 (Pubitemid 43159966)
10. Antoniou AC, Cunningham AP, Peto J, et al: The BOADICEA model of genetic susceptibility to breast and ovarian cancers: Updates and extensions. Br J Cancer 45:425-431, 2008
11. Evans DG, Shenton A, Woodward E, et al: Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a clinical cancer genetics service setting: Risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. BMC Cancer 8:155, 2008
12. Ford D, Easton DF, Stratton M, et al: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families: The Breast Cancer Linkage Consortium. Am J Hum Genet 62:676-689, 1998 (Pubitemid 28164626)
13. Turnbull C, Ahmed S, Morrison J, et al: Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet 42:504-507, 2010
14. Antoniou AC, Sinilnikova OM, McGuffog L, et al: Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet 18:4442-4456, 2009
15. Antoniou AC, Wang X, Fredericksen ZS, et al: A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet 42:885-892, 2010
16. Wang X, Pankratz VS, Fredericksen Z, et al: Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Hum Mol Genet 19:2886-2897, 2010
17. Antoniou AC, Beesley J, McGuffog L, et al: Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: Implications for risk prediction. Cancer Res 70:9742-9754, 2010
18. Antoniou AC, Shenton A, Maher ER, et al: Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers. Breast Cancer Res 8:R72, 2006
19. Andrieu N, Goldgar DE, Easton DF, et al: Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). J Natl Cancer Inst 98:535-544, 2006 (Pubitemid 43898817)
20. Narod SA, Dube MP, Klijn J, et al: Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 94:1773-1779, 2002 (Pubitemid 36004353)
21. Narod SA, Risch H, Moslehi R, et al: Oral contraceptive use reduces the risk of hereditary ovarian cancer. N Engl J Med 339:424-428, 1998 (Pubitemid 28377683)
22. Antoniou AC, Rookus M, Andrieu N, et al: Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: Results from the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev 18:601-610, 2009
23. Mitchell G, Antoniou AC, Warren R, et al: Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Res 66:1866-1872, 2006 (Pubitemid 43259974)
24. Hagen AI, Kvistad KA, Maehle L, et al: Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series. Breast 16:367-374, 2007 (Pubitemid 47157808)
25. Kriege M, Brekelmans CT, Peterse H, et al: Tumor characteristics and detection method in the MRISC screening program for the early detection of hereditary breast cancer. Breast Cancer Res Treat 102:357-363, 2007 (Pubitemid 46474846)
26. Kuhl CK, Schrading S, Leutner CC, et al: Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 23:8469-8476, 2005
27. Leach MO, Boggis CR, Dixon AK, et al: Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: A prospective multicentre cohort study (MARIBS). Lancet 365:1769-1778, 2005 (Pubitemid 40744657)
28. Trecate G, Vergnaghi D, Bergonzi S, et al: Breast MRI screening in patients with increased familial and/or genetic risk for breast cancer: A preliminary experience. Tumori 89:125-131, 2003 (Pubitemid 36745213)
29. Warner E, Hill K, Causer P, et al: Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol 29:1664-1669, 2011
30. Foulkes WD, Reis-Filho JS, Narod SA: Tumor size and survival in breast cancer: A reappraisal. Nat Rev Clin Oncol 7:348-353, 2010
31. Hagen AI, Tretli S, Maehle L, et al: Survival in Norwegian BRCA1 mutation carriers with breast cancer. Hered Cancer Clin Pract 14;7, 2009
32. Foulkes WD, Grainge MJ, Rakha EA, et al: Tumor size is an unreliable predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status. Breast Cancer Res Treat 111:199-204, 2009
33. Robson ME, Chappuis PO, Satagopan J, et al: A combined analysis of outcome following breast cancer: Differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 6:R8-R17, 2004
34. Moller P, Borg A, Evans DG, et al: Survival in prospectively ascertained familial breast cancer: Analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy. Int J Cancer 101:555-559, 2002
35. Maurice A, Evans DG, Affen J, et al: Surveillance of women at increased risk of breast cancer using mammography and clinical breast examination: Further evidence of benefit. Int J Cancer [epub ahead of print on August 23, 2011]
36. Evans DG, Gaarenstroom KN, Stirling D, et al: Screening for familial ovarian cancer: Poor survival of BRCA1/2 related cancers. J Med Genet 46:593-597, 2009